188 related articles for article (PubMed ID: 31945303)
1. Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective.
van Dijk AD; de Bont ESJM; Kornblau SM
Expert Rev Proteomics; 2020 Jan; 17(1):1-10. PubMed ID: 31945303
[No Abstract] [Full Text] [Related]
2. A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia.
Hu CW; Qiu Y; Ligeralde A; Raybon AY; Yoo SY; Coombes KR; Qutub AA; Kornblau SM
Nat Biomed Eng; 2019 Nov; 3(11):889-901. PubMed ID: 30988472
[TBL] [Abstract][Full Text] [Related]
3. The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives.
Hernandez-Valladares M; Bruserud Ø; Selheim F
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957646
[TBL] [Abstract][Full Text] [Related]
4. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.
Haubner S; Perna F; Köhnke T; Schmidt C; Berman S; Augsberger C; Schnorfeil FM; Krupka C; Lichtenegger FS; Liu X; Kerbs P; Schneider S; Metzeler KH; Spiekermann K; Hiddemann W; Greif PA; Herold T; Sadelain M; Subklewe M
Leukemia; 2019 Jan; 33(1):64-74. PubMed ID: 29946192
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
6. Proteomics approaches for myeloid leukemia drug discovery.
Kapoor I; Pal P; Lochab S; Kanaujiya JK; Trivedi AK
Expert Opin Drug Discov; 2012 Dec; 7(12):1165-75. PubMed ID: 22971110
[TBL] [Abstract][Full Text] [Related]
7. Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy.
Sjøholt G; Anensen N; Wergeland L; Mc Cormack E; Bruserud Ø; Gjertsen BT
Curr Drug Targets; 2005 Sep; 6(6):631-46. PubMed ID: 16178797
[TBL] [Abstract][Full Text] [Related]
8. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
Fernandez S; Desplat V; Villacreces A; Guitart AV; Milpied N; Pigneux A; Vigon I; Pasquet JM; Dumas PY
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336846
[TBL] [Abstract][Full Text] [Related]
9. Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines.
Aasebø E; Vaudel M; Mjaavatten O; Gausdal G; Van der Burgh A; Gjertsen BT; Døskeland SO; Bruserud O; Berven FS; Selheim F
Proteomics; 2014 Sep; 14(17-18):1971-6. PubMed ID: 25044641
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine.
Lam SS; He AB; Leung AY
Blood Rev; 2017 Nov; 31(6):418-425. PubMed ID: 28797519
[TBL] [Abstract][Full Text] [Related]
11. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
12. [Acute myeloid leukemia].
Döhner K; Paschka P; Döhner H
Internist (Berl); 2015 Apr; 56(4):354-63. PubMed ID: 25787321
[TBL] [Abstract][Full Text] [Related]
13. New drug approvals in acute myeloid leukemia: an unprecedented paradigm shift.
Kopmar NE; Estey EH
Clin Adv Hematol Oncol; 2019 Oct; 17(10):569-575. PubMed ID: 31730583
[TBL] [Abstract][Full Text] [Related]
14. Acute Myeloid Leukemia: Diagnosis and Management Based on Current Molecular Genetics Approach.
Suguna E; Farhana R; Kanimozhi E; Kumar PS; Kumaramanickavel G; Kumar CS
Cardiovasc Hematol Disord Drug Targets; 2018; 18(3):199-207. PubMed ID: 29766829
[TBL] [Abstract][Full Text] [Related]
15. Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine.
Casado P; Cutillas PR
Mol Cell Proteomics; 2023 Apr; 22(4):100517. PubMed ID: 36805445
[TBL] [Abstract][Full Text] [Related]
16. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
17. Cutting Edge Molecular Therapy for Acute Myeloid Leukemia.
Miyamoto K; Minami Y
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698349
[TBL] [Abstract][Full Text] [Related]
18. Precision therapy for acute myeloid leukemia.
Yang X; Wang J
J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
[TBL] [Abstract][Full Text] [Related]
19. Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.
Lin F; Li Z; Hua Y; Lim YP
Expert Rev Proteomics; 2016; 13(4):411-20. PubMed ID: 26954459
[TBL] [Abstract][Full Text] [Related]
20. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.
Short NJ; Konopleva M; Kadia TM; Borthakur G; Ravandi F; DiNardo CD; Daver N
Cancer Discov; 2020 Apr; 10(4):506-525. PubMed ID: 32014868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
